Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Moore

Showing results (291-300 of 303) with videos related to

Pageof 31
Sort By:
Brain : a Journal of Neurology|April 19, 2002
Human regional cerebral glucose metabolism during non-rapid eye movement sleep in relation to wakingEric A Nofzinger, Daniel J Buysse, Jean M Miewald, et al.
International Journal of Molecular Sciences|June 24, 2022
A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic LeukemiaAudrey L Smith, Alexandria P Eiken, Sydney A Skupa, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
Plos One|January 4, 2013
Unprecedented mass bleaching and loss of coral across 12° of latitude in Western Australia in 2010-11James A Y Moore, Lynda M Bellchambers, Martial R Depczynski, et al.
Plos One|August 8, 2013
Dynamic stability of coral reefs on the west Australian coastConrad W Speed, Russ C Babcock, Kevin P Bancroft, et al.
The Journal of Dermatological Treatment|June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JCI Insight|May 22, 2024
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemiaAudrey L Smith, Sydney A Skupa, Alexandria P Eiken, et al.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Phytopathology|October 24, 2008
Systematic Numbering of Vegetative Compatibility Groups in the Plant Pathogenic Fungus Fusarium oxysporumH C Kistler, C Alabouvette, R P Baayen, et al.
American Journal of Clinical Dermatology|November 1, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAndrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, et al.
Pageof 31

Showing results (291-300 of 303) with videos related to

Sort By:
Pageof 31
Brain : a Journal of Neurology|April 19, 2002
Human regional cerebral glucose metabolism during non-rapid eye movement sleep in relation to wakingEric A Nofzinger, Daniel J Buysse, Jean M Miewald, et al.
International Journal of Molecular Sciences|June 24, 2022
A Novel Triple-Action Inhibitor Targeting B-Cell Receptor Signaling and BRD4 Demonstrates Preclinical Activity in Chronic Lymphocytic LeukemiaAudrey L Smith, Alexandria P Eiken, Sydney A Skupa, et al.
The New England Journal of Medicine|November 5, 2025
Oral Icotrokinra for Plaque Psoriasis in Adults and AdolescentsRobert Bissonnette, Jennifer Soung, Adelaide A Hebert, et al.
Plos One|January 4, 2013
Unprecedented mass bleaching and loss of coral across 12° of latitude in Western Australia in 2010-11James A Y Moore, Lynda M Bellchambers, Martial R Depczynski, et al.
Plos One|August 8, 2013
Dynamic stability of coral reefs on the west Australian coastConrad W Speed, Russ C Babcock, Kevin P Bancroft, et al.
The Journal of Dermatological Treatment|June 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summaryAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
JCI Insight|May 22, 2024
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemiaAudrey L Smith, Sydney A Skupa, Alexandria P Eiken, et al.
Journal of the American Academy of Dermatology|January 22, 2024
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trialAndrew Blauvelt, Zoe D Draelos, Linda Stein Gold, et al.
Phytopathology|October 24, 2008
Systematic Numbering of Vegetative Compatibility Groups in the Plant Pathogenic Fungus Fusarium oxysporumH C Kistler, C Alabouvette, R P Baayen, et al.
American Journal of Clinical Dermatology|November 1, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 WeeksAndrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, et al.
Pageof 31